Production (Stage)
Beam Therapeutics Inc.
BEAM
$16.83
-$0.41-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.47M | 30.07M | 14.27M | 11.77M | 7.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.47M | 30.07M | 14.27M | 11.77M | 7.41M |
| Cost of Revenue | 15.73M | 101.44M | 94.26M | 87.04M | 17.65M |
| Gross Profit | -8.26M | -71.38M | -79.99M | -75.27M | -10.24M |
| SG&A Expenses | 27.94M | 28.66M | 26.52M | 29.63M | 26.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.76M | 130.10M | 120.77M | 116.67M | 111.54M |
| Operating Income | -119.29M | -100.04M | -106.50M | -104.90M | -104.13M |
| Income Before Tax | -109.27M | -90.35M | -96.67M | -91.01M | -98.67M |
| Income Tax Expenses | -- | 0.00 | -- | 39.00K | -- |
| Earnings from Continuing Operations | -109.27M | -90.35M | -96.67M | -91.05M | -98.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.27M | -90.35M | -96.67M | -91.05M | -98.67M |
| EBIT | -119.29M | -100.04M | -106.50M | -104.90M | -104.13M |
| EBITDA | -113.76M | -94.59M | -101.03M | -99.32M | -98.70M |
| EPS Basic | -1.24 | -1.09 | -1.17 | -1.11 | -1.21 |
| Normalized Basic EPS | -0.76 | -0.67 | -0.72 | -0.65 | -0.73 |
| EPS Diluted | -1.24 | -1.09 | -1.17 | -1.11 | -1.21 |
| Normalized Diluted EPS | -0.76 | -0.67 | -0.72 | -0.65 | -0.73 |
| Average Basic Shares Outstanding | 87.98M | 82.82M | 82.41M | 82.31M | 81.70M |
| Average Diluted Shares Outstanding | 87.98M | 82.82M | 82.41M | 82.31M | 81.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |